XML 45 R16.htm IDEA: XBRL DOCUMENT v3.20.1

10. SEGMENTS

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

10. SEGMENTS

The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing segment reflects the Company’s immune globulin manufacturing, commercial and development operations in Boca Raton, FL, acquired on June 6, 2017 (see Note 1). The Plasma Collection Centers segment consists of one FDA-licensed source plasma collection facility, with two additional plasma collection centers currently under construction. The Corporate segment includes general and administrative overhead expenses. The Company defines its segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. The Company’s CODM is its President and Chief Executive Officer. Summarized financial information concerning reportable segments is shown in the following tables:

Three Months Ended March 31, 2020
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated
Revenues		$	7,743,275			$	2,420,761			$	35,708			$	10,199,744
Cost of product revenue			14,451,954				2,377,272				—				16,829,226
Loss from operations			(12,476,144	)			(457,155	)			(3,836,487	)			(16,769,786	)
Interest and other expense, net			(238,873	)			—				(2,236,571	)			(2,475,444	)
Net loss			(12,715,017	)			(457,155	)			(6,073,058	)			(19,245,230	)
Capital expenditures			1,914,614				160,262				—				2,074,876
Depreciation and amortization expense			674,973				111,289				2,576				788,838
Total assets			104,645,897				5,376,807				100,501,123				210,523,827

Three Months Ended March 31, 2019
		ADMA BioManufacturing				Plasma Collection Centers				Corporate				Consolidated
Revenues		$	1,343,983			$	2,148,898			$	35,708			$	3,528,589
Cost of product revenue			7,940,346				1,464,833				—				9,405,179
(Loss) income from operations			(10,620,807	)			29,579				(2,617,188	)			(13,208,416	)
Interest and other (expense) income, net			(169,613	)			13,620				(1,268,472	)			(1,424,465	)
Gain on transfer of plasma center assets			—				11,527,421				—				11,527,421
Loss on extinguishment of debt			—				—				(9,962,495	)			(9,962,495	)
Net (loss) income			(10,790,420	)			11,570,620				(13,848,155	)			(13,067,955	)
Capital expenditures			110,453				—				—				110,453
Depreciation and amortization expense			687,393				114,241				3,696				805,330
Total assets			57,529,070				4,038,367				16,552,533				78,119,970

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Name:	us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration